Nimesulide sustained-release tablets

This product is a non-steroidal anti-inflammatory drug with anti-inflammatory, analgesic and antipyretic effects. Its mechanism of action may be related to the inhibition of prostaglandin synthesis, mediator release of leukocytes and oxidative reactions of polymorphonuclear leukocytes.

The active ingredient of this product is nimesulide. Chemical name: N-[4-nitro-2-phenoxyphenyl]methanesulfonamide Molecular weight: C13H12N2O5S

This product is light yellow tablet.

This product is a non-steroidal anti-inflammatory drug and is only used when at least one other non-steroidal anti-inflammatory drug has failed. It can be used for the pain of chronic arthritis (such as osteoarthritis), pain after surgery and acute trauma, and symptomatic treatment of primary dysmenorrhea.

Oral administration: 0.05-0.1g at a time, twice a day, after meals. The maximum single dose should not exceed 100mg, and the course of treatment should not exceed 15 days. It is recommended to use the minimum effective dose and the shortest course of treatment to reduce the occurrence of adverse drug reactions.

This product has few adverse reactions. Common adverse reactions are heartburn, stomach pain and gastrointestinal disorders, but the symptoms are mild and short-lived, and rarely require interruption of treatment. In rare cases, patients develop allergic rashes after taking it. Even if the above symptoms do not occur when using nimesulide, it should be noted that this product, like other non-steroidal anti-inflammatory drugs, may cause dizziness, drowsiness, gastric ulcers or gastrointestinal bleeding and Stevens-Johnson syndrome.

Patients with known allergy to nimesulide or any of the ingredients in this product. Patients with a history of allergy to acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs (bronchospasm, rhinitis, urticaria). Contraindicated for the treatment of perioperative pain in coronary artery bypass grafting (CABG). Patients with a history of hepatotoxic reaction to nimesulide. Patients with a history of gastrointestinal bleeding or perforation after the use of nonsteroidal anti-inflammatory drugs. Patients with active peptic ulcer/bleeding, cerebrovascular hemorrhage or other active bleeding/hemorrhagic diseases, or patients with recurrent ulcers/bleeding in the past. Patients with severe coagulation disorders. Patients with severe heart failure. Patients with severe renal impairment. Patients with liver impairment.

Precautions for children: Children under 12 years old are prohibited from using this product. Precautions for pregnancy and lactation: It has not been confirmed by experiments whether it is toxic to the fetus, and it is not recommended for pregnant women. It has not been confirmed whether this product is excreted through adult breast milk, and it is also not recommended for lactating women. Precautions for the elderly: Due to the decline in renal function, elderly patients should strictly follow the doctor's instructions for dosage, and the doctor can appropriately reduce the dosage according to the situation.

Due to the high plasma protein binding rate of this product, it may displace other protein-bound drugs. Furosemide affects the absorption of nimesulide, causing the AUC value of nimesulide to decrease by about 25%; fenofibrate, tolbutamide, and salicylic acid can displace nimesulide from plasma proteins, while furosemide, glibenclamide, and therapeutic doses of warfarin have no effect on the binding rate of nimesulide to proteins.

seal.

0.2g

18 months

Honz Pharmaceutical Co., Ltd.

• Founded in:

  1994-01-20

• Address:

  No. 6, Yaogu 3rd Road, Yaogu Industrial Park, Haikou National High-tech Industrial Development Zone, Hainan Province

• Tax NO.:

  91460000708873536T

• Registered Funds:

  455.124411 yuan

• Website:

  Log in to view

• Email:

  Log in to view